The STRIDE study did not meet its primary or secondary efficacy endpoint The company to suspend mavodelpar development and implement a workforce reduction IRVINE, Calif., Dec. 14, 2023 Reneo.
Reneo Pharmaceuticals Announces Results from Pivotal STRIDE globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
ZUG, Switzerland, Dec. 08, 2023 (GLOBE NEWSWIRE) Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the
Pharvaris Presents Deucrictibant Clinical Data And Analysis Of Endpoints For Trials Of On-Demand Treatment Of HAE At The GA²LEN UCARE Conference 2023 menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.